ArticleDiabetes, obesity & metabolism2026
Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsReal-world long-term data on oral semaglutide are limited. We evaluated its 24-month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). MATERIALS AND
methodsThis retrospective real-world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic. Changes in HbA1c, body weight, eGFR, urinary albumin-to-creatinine ratio (UACR) and lipid profile were assessed using linear mixed models. The composite endpoint of HbA1c ≤ 7% and ≥ 5% weight loss was assessed over follow-up. Treatment persistence was evaluated by Kaplan-Meier analysis, and predictors of discontinuation by multivariable Cox regression with time-dependent covariates. HbA1c and body weight before and after switching to another GLP1 receptor agonist were also evaluated.
resultsOver 24 months, oral semaglutide significantly reduced HbA1c (-0.8%; p < 0.0001) and body weight (-5.7 kg; p < 0.0001). The composite endpoint was progressively achieved by 44.0% of individuals at 24 months. Non-breakfast administration was independently associated with lower HbA1c after adjustment for BMI, age and sex (β = -0.32; p = 0.041). eGFR and UACR remained stable while total and LDL cholesterol decreased significantly (both p < 0.0001). Treatment persistence at 24 months was 68.5% (mean 19.4 months). Among discontinuers, switching to another GLP1 receptor agonist was the most common strategy (36.2%) and resulted in a further HbA1c reduction (Δ = -0.98%; p = 0.005). No safety concerns emerged.
conclusionsIn this real-world cohort, oral semaglutide provided sustained improvements in glycaemic control, body weight, and lipid profile, with preserved renal function and high treatment persistence over 24 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.